(A) Distribution of CsA nephrotoxicity lesions according to antihypertensive treatment and CsA C2 levels. (A) Distribution of CsA nephrotoxicity lesions.

Slides:

Advertisements

Similar presentations

Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema Effect of renin-angiotensin system blockade on calcium.

Advertisements

Hypertension Diagnosis and Treatment  Based on JNC 7 – published in 2003  Goal: BP

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

JNC 7 血壓分期. 血壓分期 JNC 7 ： 1. 增加高血壓前期 2.Stages 2 及 3 高血壓被合併 JNC 7, 2003.

Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Renoprotective Effect of Renin-Angiotensin-Aldosterone.

Copyright © 2015 American Medical Association. All rights reserved.

Copyright © 2005 American Medical Association. All rights reserved.

Hypertension treatment guidelines from the United Kingdom’s National Institute for Health and Care Excellence. Guidelines identify angiotensin-converting.

Effect of Renin-Angiotensin System Blockade on Calcium Channel Blocker-Associated Peripheral Edema Harikrishna Makani, MD, Sripal Bangalore, MD, MHA,

Copyright © 2015 by the American Osteopathic Association.

Copyright © 2014 American Medical Association. All rights reserved.

Copyright © 2015 by the American Osteopathic Association.

Copyright © 2004 American Medical Association. All rights reserved.

Trends in Medication Choices for Hypertension in the Elderly

Isolated Systolic Hypertension: An Update After SPRINT

Current and future paradigm for prognostication and testing of therapeutics in patients with heart failure using machine learning. Current and future paradigm.

Results of random-effects meta-analysis of association between use of angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers and.

Volume 84, Issue 2, Pages (August 2013)

Drug Rate ratio 95% CI Thiazide diuretics 1.0 Reference ACE inhibitors

Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical.

Francesco Locatelli, Lucia Del Vecchio, Simeone Andrulli, Sara Colzani

Membranous nephropathy: When and how to treat

Volume 81, Issue 7, Pages (April 2012)

Fig. 2. Evidence-based medication prescriptions

Audit-based education: a potentially effective program for improving guideline achievement in CKD patients Moniek C.M. de Goeij, Joris I. Rotmans Kidney.

Adjusted rate ratios of hospital days and admissions for blacks and Hispanics compared with whites by age group. Adjusted rate ratios of hospital days.

Volume 80, Issue 9, Pages (November 2011)

Volume 94, Issue 3, Pages (September 2018)

Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical.

Volume 72, Issue 12, Pages (December 2007)

Long-term study of mycophenolate mofetil treatment in IgA nephropathy

Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension A. Davenport, C. Cox, R. Thuraisingham Kidney.

Cardiac medications and their association with cardiovascular events in incident dialysis patients: Cause or effect? Areef Ishani, Charles A. Herzog,

Treatment Algorithm for Guideline-Directed Medical Therapy Including Novel Therapies (2,9) Green diamonds indicate Class I guideline recommendations, while.

by Ali Albasri, Suman Prinjha, Richard J McManus, and James P Sheppard

Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Rami Doukky et al. JCHF 2016;4:24-35

Effect of Renin-Angiotensin System Blockade on Calcium Channel Blocker-Associated Peripheral Edema Harikrishna Makani, MD, Sripal Bangalore, MD, MHA,

by Ali Albasri, Suman Prinjha, Richard J McManus, and James P Sheppard

The future of renoprotection: Frustration and promises

Volume 84, Issue 5, Pages (November 2013)

Distribution of average number of joint bleeds across factor activity level by age groups for patients with hemophilia B. In the boxplots, the central.

Isolated Systolic Hypertension: An Update After SPRINT

Comparative Superiority of ACE Inhibitors Over Angiotensin Receptor Blockers for People With CKD: Does It Matter? Dimitris Mavridis, PhD American Journal.

Volume 73, Issue 5, Pages (March 2008)

Volume 53, Issue 6, Pages (June 1998)

Svend A. Mortensen et al. JCHF 2014;2:

KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

Expected value of perfect implementation: population net health benefit and maximum justifiable investment if all patients who were eligible received beta.

Immunosuppression significantly reduced all-cause mortality or risk of ESRD (A) and significantly increased complete or partial remission (B) at the end.

Ionized-to-total magnesium (Mg) and calcium (Ca) ratios are lower in patients on hemodialysis than those in patients not on dialysis. Ionized-to-total.

Drug factors associated with increased risk for nephrotoxicity.

Ratio of actual to expected rise in sodium as calculated using the Adrogué-Madias formula. Ratio of actual to expected rise in sodium as calculated using.

Dialyzer clearance of ampicillin/sulbactam in plasma of critically ill patients with AKI undergoing extended dialysis. Dialyzer clearance of ampicillin/sulbactam.

Unadjusted odds ratio of death at 6 mo for medications (β blockers [BBL], angiotensin-converting enzyme inhibitors [ACEI]/angiotensin receptor blockers.

Friends, social networks, and progressive chronic kidney disease

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is.

Serum bicarbonate increased by ≥3, ≥4, and ≥5 mEq/L in 52%, 39%, and 22% of patients, respectively, in the combined TRC101 dose group compared with 6%,

Combination angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) reduced risk for renal end point versus ACEI or ARB. Effect.

An updated general approach for achieving BP goals in people with diabetes. An updated general approach for achieving BP goals in people with diabetes.

Kaplan-Meier analysis for the cumulative percentage of patients who remained hospitalized according to presence or absence of ARF with or without other.

Adjusted hazard ratio (AHR) of final AVF failure by percent consistent facility aspirin use. Adjusted hazard ratio (AHR) of final AVF failure by percent.

Percentage of patients found with a kidney function too low for recommended use of the drug using estimated glomerular filtration rate compared with creatinine.

Distribution of percent consistent facility aspirin use.

New dialysis starts in the United States by year in patients with and without diagnosis of diabetes. New dialysis starts in the United States by year in.

Aliskiren, the orally effective renin inhibitor, provides antihypertensive efficacy at least equivalent to the ARB irbesartan in patients with hypertension.

Kaplan-Meier curve of the primary outcome in patients prescribed ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB). Kaplan-Meier curve of the.

Distribution of facility mean treatment time, by DOPPS region and phase. Distribution of facility mean treatment time, by DOPPS region and phase. Restricted.

Presentation transcript:

(A) Distribution of CsA nephrotoxicity lesions according to antihypertensive treatment and CsA C2 levels. (A) Distribution of CsA nephrotoxicity lesions according to antihypertensive treatment and CsA C2 levels. Circles are filled to indicate the presence of CsA nephrotoxicity as indicated in the legend. cPatients with combined treatment with calcium channel blocker (CCB) and angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB). (B) Odds ratios for the development of overt CsA toxicity. The population was divided using various cutoffs of CsA C2 levels. CsA C2 levels were calculated for each patient as the average of all levels measured during a period of 2 yr before each biopsy. Odds ratios are adjusted for the use of ACEIs or ARBs. Horizontal bars indicate low and high 95% confidence intervals. *P < 0.03. Severin-Wafo Kengne et al. CJASN 2009;4:1409-1416 ©2009 by American Society of Nephrology